Oligonucleotide synthesis with alternative solvents
CA 2540692 C · Owner: Isis Pharmaceuticals, Inc. · Inventors: Moore, Max N.; Krotz, Achim; Carty, Recaldo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides for methods of manufacturing an oligonucleotide comprising a pentavalent phosphate triester. In particular the method , comprises providing a 5' blocked-nucleoside deblocking the 5' blocked-, nucleoside to form a 5' OH-nucleoside coupling the 5' OH-nucleoside with a , phosphoramidite to form and oligonucleotide comprising a trivalent phosphite triester; and oxidizing the oligonucleotide comprising a trivalent phosphite triester to the oligonucleotide comprising a pentavalent phosphate triester. In some embodiments, the wash between any of the steps above is with at least one solvent wash comprising a toluene.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 2, 2004 and granted May 28, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 2, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 2, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.